NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Elanco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On August 9, 2021, Elanco issued a press release reporting its financial results for the second quarter of 2021. Among other items, Elanco lowered its adjusted EPS forecast to $0.97 - $1.03, down from the previous guidance of $1.00 to $1.06. In addition, Elanco disclosed receipt of a U.S. Securities and Exchange Commission subpoena regarding its channel inventory and sales practices before mid-2020. On this news, Elanco's stock price fell sharply during intraday trading on August 9, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.